Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ipsen To Acquire Tercica | Contract Pharma

What are you searching for?

Sign in
Breaking News

Ipsen To Acquire Tercica

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ipsen, S.A. and Tercica have entered into a definitive merger agreement under which an affiliate of Ipsen will acquire all outstanding shares (approximately 43%) of Tercica for approximately $663 million in cash. This transaction, which is subject to approval by Tercica stockholders, has been approved by Tercica’s board of directors.

“The combination of Ipsen’s and Tercica’s development and product portfolios provides the opportunity to create a leading global endocrinology company,” said John A. Scarlett, M.D., chief executive officer of Tercica. “We believe this transaction recognizes the value we have created at Tercica and provides our stockholders with attractive financial terms.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters